Evaluation of Treatment With Interferon, Octreotide, or Their Combination in Patients With Zollinger-Ellison Syndrome and Progressive Metastatic Non-B Islet Cell Neoplasm
Heretofore morbidity and mortality in Zollinger-Ellison syndrome were caused by severe ulcer
disease. The advent of specific drugs to cure ulcer disease now extends life until
metastases from the non-B-islet cell tumor or other events cause death. Patients with
metastatic gastrinoma that is not surgically resectable and that has increased in size over
a 4-6 month period prior to the study will be treated with interferon-alpha, 5 million
international units/day. The drug will be administered subcutaneously by the patient.
Tumor response and side effects will be monitored. Patients will receive 6 months of
therapy and if there is reduction or stabilization of tumor masses, therapy will continue as
long as response is maintained.
Primary Purpose: Treatment
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|